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the CC BY-NC-ND license (http://creaAbstract Objective: Extracapsular extension (ECE) of prostate cancer is a poor prognostic
factor associated with progression, recurrence after treatment, and increased prostate can-
cer-related mortality. Accurate staging prior to radical prostatectomy is crucial in avoidance
of positive margins and when planning nerve-sparing procedures. Multi-parametric magnetic
resonance imaging (mpMRI) of the prostate has shown promise in this regard, but is hampered
by poor sensitivity. We sought to identify additional clinical variables associated with patho-
logic ECE and determine our institutional accuracy in the detection of ECE amongst patients
who went on to radical prostatectomy.
Methods: mpMRI studies performed between the years 2012 and 2014 were cross-referenced
with radical prostatectomy specimens. Predictive properties of ECE as well as additional clinical
and biochemical variables to identify pathology-proven prostate cancer ECE were analyzed.
Results: The prevalence of ECE was 32.4%, and the overall accuracy of mpMRI for ECE was 84.1%.
Overall mpMRI sensitivity, specificity, positive predictive value, and negative predictive value for
detection of ECE were 58.3%, 97.8%, 93.3%, and 81.5%, respectively. Specific mpMRI characteris-
tics predictive of pathologic ECE included primary lesion size ((20.73  9.09) mm, mean  SD,
p < 0.001), T2 PIRADS score (pZ 0.009), overall primary lesion score (p < 0.001), overall study
suspicion score (pZ 0.003), and MRI evidence of seminal vesicle invasion (SVI) (pZ 0.001).
Conclusion: WhilempMRI is an accurate preoperative assessment tool for thedetection of ECE, its
overall sensitivity is poor, likely related to the low detection rate of standard protocol MRI fordu (M.A. Vira).
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32 G.S. Gaunay et al.microscopic extraprostatic disease. The additional mpMRI findings described may also be consid-
ered in surgical margin planning prior to radical prostatectomy.
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licenses/by-nc-nd/4.0/).1. Introduction
The presence of pathologic extracapsular extension (ECE)
of prostate adenocarcinoma after radical prostatectomy is
a poor prognostic factor associated with recurrence and
progression, as well as an increased risk of prostate cancer-
related mortality [1,2]. ECE may also contribute to positive
surgical margins during prostatectomy, an independent
predictor of prostate specific antigen (PSA) progression
after surgery [3]. While some suggest robot-assisted radical
prostatectomy (RARP) may safely be performed in patho-
logic T3 (pT3) disease, preoperative concern for ECE often
impacts the decision to pursue a nerve-sparing procedure, a
decision that may detrimentally affect erectile function
and quality of life after surgery [4].
Accurate clinical staging is essential to the clinician
when counseling regarding treatment modalities and sur-
gical planning. However, existing staging tools are woefully
inaccurate. Transrectal ultrasonography (TRUS) and digital
rectal exam (DRE), even in combination, are hampered by
insufficient sensitivity and specificity for extraprostatic
disease [5]. Additional predictive tools, such as pretreat-
ment algorithms like the Partin tables and the Memorial
Sloan Kettering (MSK) nomogram, were developed for the
prediction of pathologic stage [6,7]. These widely used
tools consider factors, such as biopsy Gleason score, clinical
staging, and PSA, in their analyses. Variability in reported
accuracy rates of these nomograms and their inability to
predict site-specific ECE necessitates a more clinically
applicable, accurate tool for the differentiation of extrap-
rostatic and organ-confined (OC) prostate cancer [6e10].
In recent years multi-parametric magnetic resonance
imaging (mpMRI) of the prostate has emerged as an integral
tool in the staging and, more recently, diagnosis of prostate
cancer. Although its role is not currently clearly defined in
management algorithms, both the National Comprehensive
Cancer Network (NCCN) and European Association of Urology
(EAU) recommend its use as a staging adjunct in high-risk
disease [11,12].
mpMRI may provide prognostic information integral to
treatment counseling and the management of expecta-
tions. When combined with clinical nomograms, mpMRI has
been shown to improve the overall diagnostic accuracy of
OC prostate cancer [13]. Alone, mpMRI has been shown to
outperform the Partin tables in the detection of ECE and
prediction of organ-confined disease [14,15]. Moreover,
patients with clinical T3 disease on MRI have twice the risk
of prostate cancer-specific mortality (PCSM) versus those
with clinical T1/T2 and occult pT3 disease upstaged on final
pathology [16]. Unfortunately, reported sensitivity and
specificity of mpMRI in the detection of ECE is variable.
Additionally, correlation studies of mpMRI and histopa-
thology have demonstrated inconsistent tumor volumeestimation, particularly in large tumors, in which size is
often underestimated [17,18].
Despite these limitations, mpMRI represents an impor-
tant step forward in the clinical staging of prostate cancer.
It is our aim to identify specific mpMRI variables that pre-
dict an increased likelihood of ECE and pT3 disease
following prostatectomy in patients with clinically localized
prostate cancer.2. Materials and methods
2.1. Study design
We queried our prospectively maintained, Institutional Re-
view Board-approved database of 1722 3-T (T)mpMRI studies
performed within the Northwell Health System between the
years 2012 and 2014. 3-T MRI included use of both endorectal
and phase array cardiac coil. Functional analyses, consisting
of dynamic contrast enhanced (DCE) and diffusion weighted
imaging (DWI) modalities, are standard. Positive mpMRI was
defined as the presence of one or more radiographically
detected lesions. Primary and secondary lesions (based on
overall size in mm) were assessed for peripheral versus
central location, laterality, associated apparent diffusion
coefficient (ADC) and prostate imaging reporting and data
system (PIRADS) scores. In this scoring system each param-
eter (T2 Weighted Imaging (T2WI), DWI, DCE) is graded on a
5-point Likert scale. An additional overall 5-point score is
given to the lesion as a whole, corresponding to the risk
of clinically significant cancer, per the recommendations of
the European Society of Urogenital Radiology (ESUR) [19].
Additional MRI variables such as capsular bulging, overt ECE
and seminal vesicle involvement (SVI), and number of
visualized lesions were also assessed. mpMRI studies were
cross-referenced with radical prostatectomy specimens
received within study duration. All prostatectomy speci-
mens were centrally reviewed by dedicated uropathologists.
mpMRI accuracy was defined as concordance between MRI
findings suggestive of and pathologic evidence of ECE.
2.2. Statistical analysis
Descriptive statistics are presented as counts and per-
centages for categorical variables and as means and SD for
continuous variables. The association of baseline clinical,
biochemical, and MRI-related variables with pathology-
proven prostate cancer ECE (present or absent) was
analyzed with Student’s t test for continuous data and chi-
square test for categorical variables in univariable analysis.
The following clinical and biochemical variables analyzed
included: PSA (continuous, in mg/L), prostate volume
(continuous, in mL), fusion biopsy (yes or no), MRI result
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ting capsule (yes or no), bulging (yes or no), ECE on MRI (yes
or no), SVI on MRI (yes or no), number of lesions (contin-
uous), and primary and secondary lesions size (continuous,
in mm), zone (central or peripheral), laterality (right,
middle, or left), ADC (continuous, in 106 mm2/s), T2
PIRADS score (1e5), diffusion PIRADS score (1e5),
enhancement PIRADS score (1e5) and overall lesion score
(1e5). We also evaluated the predictive properties of ECE
on MRI to identify pathology-proven prostate cancer ECE.
Estimates are presented with 95% confidence interval (CI).
All statistical analyses were two-tailed and performed using
R 3.2.2 (R Foundation for Statistical Computing, Vienna,
Austria). A p < 0.05 was considered statistically significant.
3. Results
A total of 74 patients underwent radical prostatectomy
after mpMRI, and the descriptive pathologic statistics are
presented in Table 1. OC disease (pT2) was found in 49
(66.2%) patients. Overall prevalence of ECE was 32.4%
(n Z 24), with five cases being indeterminate on final pa-
thology. Of the patients with ECE, eight had disease with
SVI. One patient had solitary SVI. Two specimens, both
pT3b, demonstrated lymphovascular invasion.Table 1 Radical prostatectomy characteristics found on
surgical pathology (n Z 74).
Characteristic Value
Prostate size (g)a 51.8  19.7
Gleason score
6 18 (24.3)
7 42 (56.8)
8 11 (14.9)
9 2 (2.7)
10 1 (1.4)
Tumor quantification
Minimal (<10%) 5 (6.8)
Moderate (10%e50%) 64 (86.5)
Extensive (>50%) 5 (6.8)
Tumor stage
pT2 49 (66.2)
pT3a 16 (21.6)
pT3b 9 (12.2)
Extracapsular extension
Absent 45 (60.8)
Present 24 (32.4)
Indeterminate 5 (6.8)
Positive surgical margins
Absent 54 (73.0)
Present 19 (25.7)
Indeterminate 1 (1.4)
Seminal vesicle invasion
Absent 65 (87.8)
Present 9 (12.2)
Lymphovascular invasion
Absent 72 (97.3)
Present 2 (2.7)
a Data presented asmean SD, and n (%) for other parameters.The overall accuracy of mpMRI for ECE was 84.1%. mpMRI
sensitivity, specificity, positive predictive value, and
negative predictive value for detection of ECE were 58.3%,
97.8%, 93.3%, and 81.5%, respectively.
Table 2 summarizes characteristics of prostate MRI,
broken down by pathology-proven ECE. The five patients
with indeterminate ECE result on pathology were excluded
from this analysis. Additional mpMRI characteristics asso-
ciated with pathologic ECE were primary lesion size
((20.73  9.09) mm, mean  SD, p < 0.001), T2 PIRADS
score (pZ 0.009), overall primary lesion score (p < 0.001),
overall study suspicion score (pZ 0.003), and MRI evidence
of SVI (p Z 0.001). Neither MRI presence of capsular
abutment nor bulging was significantly associated with
pathologic ECE (p Z 1.000 and p Z 0.173, respectively).
4. Discussion
mpMRI is a well-established adjunct in the clinical staging
of prostate cancer, improving detection of ECE versus that
of clinical nomograms, which routinely understage 25%e
30% of patients [20]. In this study, we have demonstrated
the excellent specificity, but limited sensitivity, of mpMRI
for the presence of ECE and pT3 disease. The limited
sensitivity reported in many prior studies examining mpMRI
prediction of ECE reflects the inability of MRI to detect
microscopic capsular penetrance.
In their meta-analysis of 75 studies encompassing 9796
patients, de Rooij et al. [21] sought to comprehensively
examine the staging accuracy of MRI of the prostate.
Excellent overall specificity of 91% and 88%, for the
detection of ECE and overall T3 staging, was found
respectively. In contrast, overall sensitivity was less reli-
able at 57% and 61%, respectively. This study included a
variety of differing MRI protocols, many of which employed
a single or no functional components (i.e., DWI, DCE, or MR
spectroscopic imaging (MRSI)), an integral component of
prostatic MRI [21]. Both the American Society of Radiology
(ACR) and the European Society of Uroradiology recom-
mend use of two or more functional studies [19,22]. On
whole in the subset of protocols using functional phases,
some of which included only one functional component,
overall sensitivity and sensitivity were improved (62%) and
reduced (86%), respectively, in overall clinical T staging.
DWI and determination of ADC is particularly funda-
mental in evaluation of peripheral zone lesions and has
shown superior sensitivity vs. T2WI alone [23e28]. Cancer
on DWI presents with lower ADC values than that of normal
tissue, the degree of which may be correlated to Gleason
score [29,30]. Underscoring the importance of DWI further,
Giganti et al. [31] generated a novel nomogram combining
mpMRI, including ADC from DWI, along with clinical factors
aiming at side-specific ECE prediction. Sensitivity was
significantly improved vs T2WI (88% vs. 54%). Interestingly,
in our study, T2WI PIRAD scoring was predictive of ECE
while DWI was not. While T2WI has shown independent
concordance with pathologic ECE, the absence of DWI
concordance is puzzling [27]. ADC of secondary lesions,
when observed, was also found to be predictive of patho-
logic ECE, while primary lesion’s ADC was not. It is well
established that DWI is superior to T2WI for evaluation of
Table 2 Prostate MRI characteristics by pathology-proven prostate cancer extracapsular extension.
Variable Extracapsular extension p-Value
Absent Present
n (%) 45 (65.2) 24 (34.8) N/A
MRIa 0.067
Negative 13 (28.9) 2 (8.3)
Positive 32 (71.1) 22 (91.7)
Overall suspicion scorea 0.003
2 5 (20.8) 1 (6.3)
3 6 (25.0) 1 (6.3)
4 11 (45.8) 4 (25.0)
5 2 (8.3) 10 (62.5)
Abutting capsulea 1.000
No 43 (95.6) 23 (95.8)
Yes 2 (4.4) 1 (4.2)
Bulginga 0.173
No 43 (95.6) 20 (83.3)
Yes 2 (4.4) 4 (16.7)
MRI: extracapsular extensiona <0.001
No 44 (97.8) 10 (41.7)
Yes 1 (2.2) 14 (58.3)
MRI: seminal vesicle invasiona 0.001
No 45 (100.0) 18 (75.0)
Yes 0 (0.0) 6 (25.0)
Number of lesionsb 1.0  0.9 1.4  0.9 0.119
Primary lesion
Lesion size (mm)b 11.55  4.88 20.73  9.09 <0.001
Zonea 1.000
Central 6 (19.4) 5 (22.7)
Peripheral 25 (80.6) 17 (77.3)
Lateralitya 0.007
Right 20 (64.5) 5 (22.7)
Left 9 (29.0) 12 (54.5)
Middle 2 (6.5) 5 (22.7)
ADC (106 mm2/s)b 752.6  241.2 623.1  166.9 0.069
T2 PIRADS scorea 0.009
3 5 (29.4) 1 (8.3)
4 11 (64.7) 4 (33.3)
5 1 (5.9) 7 (58.3)
Diffusion PIRADS scorea 0.773
3 1 (5.9) 0 (0.0)
4 3 (17.6) 1 (8.3)
5 13 (76.5) 11 (91.7)
Enhancement PIRADS scorea 0.164
1 1 (5.9) 0 (0.0)
2 2 (11.8) 0 (0.0)
3 3 (17.6) 0 (0.0)
4 11 (64.7) 12 (100.0)
Overall lesion scorea <0.001
3 4 (23.5) 0 (0.0)
4 13 (76.5) 3 (25.0)
5 0 (0.0) 9 (75.0)
ADC, apparent diffusion coefficient; MRI, magnetic resonance imaging; PIRADS, prostate imaging reporting and data system; PSA,
prostate-specific antigen; SD, standard deviation.
a Data presented as n (%).
b Data presented as mean  SD.
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findings in the current study is not immediately apparent,
but may owe to low study numbers.
mpMRI may enable more precise surgical strategy, as
opposed to reliance on risk group stratification. Evidence of
ECE on mpMRI should influence margin planning at the time
of radical prostatectomy. Indeed, as many as 30%e50% of
men categorized as high-risk by D’Amico criteria may have
OC disease; however, these patients are likely to undergo
non-nerve-sparing surgery due to the imprecise clinical risk
assessment [33,34]. Analysis of ECE prediction based on
ESUR scoring on mpMRI in prostate cancer patients strati-
fied by NCCN risk groups demonstrated excellent predictive
value, even amongst the high-risk cohort. Retrospective
review showed 25.7% of men who had no evidence of ECE on
mpMRI and who underwent a non-nerve-sparing procedure
due to high-risk features, ultimately had OC disease at final
pathology. Conversely, mpMRI was able to predict patho-
logic ECE in low or intermediate risk patients in patients
who underwent nerve-sparing procedures and subsequently
had a positive surgical margin [35].
Tamada et al. [36] retrospectively analyzed a group of
56 men with prostate cancer who underwent 3-T mpMRI
prior to radical prostatectomy and found similar results.
Positive surgical margins, found in 27% of patients, were
linked with MRI findings suggestive of ECE, as well as lower
tumor ADC and extension into the proximal or apical pros-
tate. Despite this, small foci of ECE may not be detectable,
especially when localized in the prostatic apex, again ac-
counting for low sensitivity [37].
Ultimately, the ability ofMRI to detectedECE has themost
utility in surgical planning. In a recent study, investigators
incorporated MRI in the preoperative decision to preserve or
sacrifice the neurovascular bundles in a group of 353 men
scheduled to undergo robotic radical prostatectomy.
Following review, 26% of initial surgical plans were changed.
In the procedures altered due to MRI findings, 91% of those
changed to nerve sparing and 63% of those changed to neu-
rovascular bundle resecting were appropriate, demon-
strating the benefit ofmpMRI staging in clinical practice [38].
In this study we have identified several independent
mpMRI predictors of pathologic ECE. Unfortunately, wewere
unable to identify any correlation between these indepen-
dent variables and pathologic ECE in the setting of negative
mpMRI, given low study numbers. Van Holsbeeck et al. [39],
Cornud et al. [40], and Baco et al. [41] found beneficial
improvements in sensitivity (85.2% vs. 57.4%) and moderate
decrease in specificity (83.9% vs. 91.9%) for mpMRI detection
of ECE with the addition of “indirect signs”, including
capsular bulging and tumor contact length greater than
>20 mm. An additional predictor not examined in our anal-
ysis, tumor contact length above a threshold of 20 mm has
been shown to be superior to that of conventional MRI
criteria [41]. MRI mean lesion size was found to be inde-
pendently predictive of pathologic ECE. Larger index lesion
size (>0.5 mL) has been correlated to increased risk of
positive surgical margin after RALP [42]. This may indicate a
potential role for wider surgical margins, even in the
absence of discrete mpMRI evidence of ECE.
There are several limitations to this study. The overall
number of patients with ECE included in the study was
small and findings were generated through retrospectivereview at a single institution. Also, MRI accuracy is depen-
dent on experienced radiologic review. Inexperience may
negatively impact the sensitivity and specificity of mpMRI
by as much as 9% and 37%, respectively [43]. Our studies
were read by one of two fellowship trained uro-radiologists.
Further multi-institutional, prospective trials are necessary
to confirm generalizability of the findings herein. Future
research will need to address the role of mpMRI suspicion
versus that of clinical risk stratification profiles and nomo-
grams in the clinical assessment of ECE.
5. Conclusion
mpMRI is able to predict pathologic ECE with excellent
specificity, but poor specificity. Several additional variables
detected on mpMRI were found to be independently pre-
dictive of pathologic ECE in this study and may assist with
preoperative staging.
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